ENDRA Life Sciences Further Strengthens TAEUS® System Intellectual Property with Issuance of 22nd and 23rd U.S. Patents
November 16 2021 - 9:15AM
Business Wire
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of
Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the
United States Patent and Trademark Office has issued two patents,
including U.S. Patent No. 11172829 (the ‘829 patent) titled
“Thermoacoustic Transducer With Integrated Switch,” and U.S. Patent
No. 11176848 (the ‘848 patent) titled “Tissue-mimicking Material
for A Multi-modality Imaging Phantom.”
- The ‘829 patent relates to a novel system for reducing false
signals in thermoacoustic imaging. This patent enables mitigation
of radiofrequency energy effects upon the electronic components of
the system. ENDRA expects the ‘829 patent to be effective for all
thermoacoustic imaging applications.
- The ‘848 patent relates to ENDRA’s novel phantom for use with
different imaging modalities including thermoacoustic imaging,
ultrasound imaging and MRI. This patent enables health
practitioners to use a single phantom instead of multiple phantoms
when calibrating or validating a thermoacoustic system for use. The
‘848 patent should be particularly valuable as ENDRA proceeds with
clinical trials in multiple countries.
“These issued patents – our 22nd and 23rd in the U.S. – support
our strategy to develop optimized hybrid ultrasound and
thermoacoustic imaging systems and to broaden the potential
applications for our proprietary TAEUS® technology in areas with
unmet clinical needs," stated ENDRA's Chief Executive Officer
Francois Michelon. "We continue to enhance our intellectual
property portfolio to protect our technology in priority global
markets. Our portfolio currently stands at 89 assets, which we
define as patents issued, filed or in preparation.”
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
400,000 cart-based ultrasound systems in use globally today. TAEUS®
is initially focused on the measurement of fat in the liver as a
means to assess and monitor Non-Alcoholic Fatty Liver Disease
(NAFLD) and inflammation (NASH), chronic liver conditions that
affect over one billion people globally, and for which there are no
practical diagnostic tools. Beyond the liver, ENDRA is exploring
several other clinical applications of TAEUS®, including
visualization of tissue temperature during energy-based surgical
procedures. For more information, please visit
www.endrainc.com.
Forward-Looking Statements
All statements in this news release that are not based on
historical fact are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements, which
are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of forward-looking terms such as "believe," "expect," "may,"
"will," "should," "could," "seek," "intend," "plan," "goal,"
"estimate," "anticipate" or other comparable terms. Examples of
forward-looking statements for ENDRA include, among others,
estimates of the timing of future events and achievements, such as
the expectations regarding the transition of leadership of ENDRA’s
finance function, and expectations concerning ENDRA's business
strategy, which may be affected by risks related to the impact of
COVID-19 on its business plan, its ability to find and maintain
development partners, market acceptance of its technology and the
amount and nature of competition in its industry, its ability to
protect its intellectual property, and other risks and
uncertainties described in its filings with the Securities and
Exchange Commission. Forward-looking statements involve inherent
risks and uncertainties that could cause actual results to differ
materially from those in the forward-looking statements as a result
of various factors including, among others, our ability to develop
a commercially feasible technology; receipt of necessary regulatory
approvals; the impact of COVID-19 on our business plans; our
ability to find and maintain development partners, market
acceptance of our technology and the amount and nature of
competition in our industry; our ability to protect our
intellectual property; and the other risks and uncertainties
described in ENDRA's filings with the Securities and Exchange
Commission. The forward-looking statements made in this news
release speak only as of the date of issuance, and ENDRA assumes no
obligation to update any such forward-looking statements to reflect
actual results or changes in expectations, except as otherwise
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211116005938/en/
Company: Irina Pestrikova Senior Director, Finance
investors@endrainc.com www.endrainc.com
Investor Relations: Yvonne Briggs LHA Investor Relations
(310) 691-7100 YBriggs@lhai.com
Media: Jules Abraham JQA Partners, Inc. (917) 885-7378
jabraham@jqapartners.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Sep 2023 to Sep 2024